PD-0332991
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle-Cell
Conditions
Lymphoma, Mantle-Cell
Trial Timeline
May 1, 2007 → Mar 1, 2012
NCT ID
NCT00420056About PD-0332991
PD-0332991 is a phase 1 stage product being developed by Pfizer for Lymphoma, Mantle-Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT00420056. Target conditions include Lymphoma, Mantle-Cell.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01356628 | Phase 2 | Completed |
| NCT00420056 | Phase 1 | Completed |
| NCT00141297 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoma, Mantle-Cell